NCT07247292Terminated
Epidemiological Study of Treatment Approaches on AQP4-IgG Positive NMOSD in Russia
A Multicenter Non-interventional Single-arm Retrospective-prospective Observational Study in Therapeutic Approaches on AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder (NMOSD) in Real Clinical Practice in Russia
Source: ClinicalTrials.gov · Last updated 21 Jul 2026
Brief summary (registry, in English)
This is a multi-centre, retrospective-prospective, single-arm, non-interventional (observational) cohort study with secondary data collection within real-world settings of participants with AQP4-IgG positive NMOSD.
- Status (registry)
- Terminated
- Study type
- Observational
- Enrollment
- 3 (actual)
- First submitted
- 18 Nov 2025
- Start date
- 23 Dec 2025
- Primary completion date
- 26 Feb 2026
- Lead sponsor
- AstraZeneca
- Diseases
- Neuromyelitis optica (NMOSD)
- NCT number
- NCT07247292
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- 1.Participants currently enrolled in clinical studies for the treatment of NMOSD.
Who the study is looking for
- Adults (≥18 years) with a confirmed diagnosis of AQP4-IgG positive NMOSD following the 2015 IPND criteria;
- Provision of signed and dated written informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - | Novosibirsk | Russia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.